An observational study in Seizure, Epileptic, sponsored by Wei Zhao. Recruiting at 1 site in China. Open to participants aged 65 Years to 100 Years. Per ClinicalTrials.gov, last updated 2022-07-15.
Sponsored by Wei Zhao · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Seizures with a site in China — 14 open to participants now, 16 under way, 9 of them phase 3. Seizures · China.
Among the 39 studies in Seizures with a site in China, this one is the 6th largest by planned enrollment of the 13 observational ones that give a count, is one of 4 that started in 2021, is one of 13 observational ones, reaches primary completion later than 13 of the 15 other live ones, and was the 30th registered.
766 studies on the registry are indexed under Seizures; 133 are open to participants now.
Browse Seizures studies →14 of the 39 studies in Seizures with a site in China are open now. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18–75
Epygenix · Sites in China, United States, Hungary and 7 more countries
Ages 2–55
UCB Biopharma SRL · Sites in China, United States, Australia and 10 more countries
Ages 12+
Epygenix · Sites in China, United States, Argentina and 8 more countries
Ages 2+
yuanli Zhao · Sites in China
Ages 18–70 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 92 Seizures studies recruiting now, 36 (39%) set no upper age limit and 43 (47%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.
This study: 65 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 19
First in 2006; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 140 across 216 observational studies indexed under Seizures.
Median enrollment 280 across the 26 interventional studies, 500 across the 13 observational. Of the 17 that completed or were terminated, 11 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 39 have an industry lead sponsor. The 10 most frequent:
Wei Zhao is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Wei Zhao has 1 study filed under Seizures — fewer than ten, so there is no comparison to draw.
7 of the studies in Seizures with a site in China that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT07239115Phase 3Beijing Tiantan HospitalLevetiracetam for Seizure Prevention After Brain Tumor Surgery | 2027-01 |
| NCT05077904Phase 3UCB Biopharma SRLA Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures | 2027-03-29 |
| NCT04462770Phase 3EpygenixA Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome | 2027-04 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
Add all 7 to your calendar (.ics) → With an account.
Among the 39 studies in Seizures with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose is to study the population pharmacokinetics, effectiveness and safety of antiepileptic drug (phenytoin, carbamazepine, lamotrigine, levetiracetam, parempanel, etc) in elderly patients and recommend optimized dosage regimens.
Elderly patients with epilepsy (≥65years).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The use of antiepileptic drugs depends on the clinical practice.
Drug: antiepileptic drugs
phenytoin, carbamazepine, lamotrigine, levetiracetam, perampanel, etc. as part of routine treatment.
The peak plasma drug concentration of antiepileptic drugs.
To detect the peak plasma drug concentration of antiepileptic drugs.
Time frame: at (0-4) h after oral administration
The random plasma drug concentration of antiepileptic drugs.
To detect the random plasma drug concentration of antiepileptic drugs.
Time frame: at (4-10) h after oral administration
The trough plasma drug concentration of antiepileptic drugs.
To detect the trough plasma drug concentration of antiepileptic drugs.
Time frame: at (1-2) h before the next administration
The incidence of adverse drug reaction
Time frame: Through study completion, an average of 14 days
The frequency of seizures
Time frame: Through study completion, an average of 14 days
Started Jan 2021 (actual). Primary completion is estimated for Mar 2028, 86 months after the start.
Of 53 non-industry observational studies under Seizures, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 18. This study's planned 86 months is above that.
Counting every sponsor, half of 80 studies reached it within 37 months; a quarter within 18 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wei Zhao